In short
Clinical trials of Alglucosidase Alfa are studying enzyme therapy in people with Pompe disease. These studies look at safety, treatment effects, quality of life, and health costs in children and adults, including older adults with stable late-onset Pompe disease. They also explore whether treatment can be given less often or tracked over time.
Key points
- Clinical trials of Alglucosidase Alfa are being done in Pompe disease, including children, adults, and selected older adults with stable late-onset disease. Both studies are Phase 3 and are authorised. One trial tests whether treatment can be given less often without worsening muscle, breathing, or daily function. The other study looks at long-term clinical effects, quality of life, survival, heart and lung outcomes, hearing, fatigue, and costs. Together, the trials focus on treatment effects, safety, and how care may be improved over time.
Trial overview
Two authorised Phase 3 studies are investigating Alglucosidase Alfa in people with Pompe disease. Both studies are interventional, which means the researchers assign a treatment plan and then measure what happens.
The trials are focused on treatment effects in real patients, not on laboratory-only research. They look at muscle strength, movement, breathing, quality of life, and other outcomes that matter in daily life.
Who is being studied
One trial includes a selected group of elderly patients with late-onset Pompe disease (LOPD) who are stable and do not need wheelchair use or daytime breathing support while awake and seated. The brief summary also says these patients are not at immediate risk of losing the ability to do important daily activities.
The second trial includes children and adults with Pompe disease, also listed as glycogenosis type II and acid maltase deficiency. This wider age range allows the study to look at long-term effects across different stages of life.
What the trials measure
The studies measure several efficacy outcomes, which means how well the treatment works. These include muscle strength, muscle function, breathing function, and patient-reported outcomes such as quality of life.
Safety is also part of the research. The first study records vital signs, weight, treatment-emergent adverse events, and infusion-associated reactions.
The second study goes beyond treatment effect and also measures survival, motor and mental outcome, cardiac hypertrophy and function, hearing loss, disease-specific symptoms, fatigue, muscle mass and regeneration, and costs.
TRIPO-Study: less frequent treatment in stable late-onset Pompe disease
The TRIPO-Study asks whether enzyme replacement therapy can be given once every 4 weeks instead of once every 2 weeks without causing more disease progression. The researchers want to see whether this less frequent schedule keeps muscle strength, muscle function, and lung function stable over 9 months.
If the lower-frequency schedule is safe and does not lead to worse disease progression, the study also plans to explore whether treatment could eventually be stopped. This makes the study important for patients who are stable and may not need the same treatment frequency forever.
The main endpoints include manual muscle testing (MMT) and hand-held dynamometry (HHD) for strength, 6-minute walk test (6MWT) and quick motor function test (QMFT) for movement, and breathing tests such as forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP). Patient-reported measures include the modified Rasch-built Pompe-specific activity (mR-PAct) scale and SF-36, which is a quality-of-life questionnaire.
Long-term effects and health economic study in children and adults
The second study looks at the long-term clinical effects of enzyme therapy in children and adults with Pompe disease. One goal is to improve care and to support reimbursement decisions by Dutch health authorities after the first 3 years.
This trial also studies the economic burden of Pompe disease, which means the total costs of care, informal care, and loss of productivity. The researchers want to see how enzyme therapy affects these costs and whether care can be made more efficient.
Other goals include learning when to start or stop enzyme therapy, whether dosing should be based on body weight or lean body mass, and whether home treatment can be safely arranged. The study also aims to learn more about muscle wasting, called atrophy, and the ability of skeletal muscle to rebuild, called regeneration.
The main outcomes are survival, muscle strength and function, motor and mental outcome, breathing function, heart changes, hearing loss, disease-specific symptoms, handicap, quality of life, fatigue, muscle mass, regeneration, and costs.
How to read the trial results
These studies are not the same as a simple treatment guide; they are research projects designed to answer specific questions about care in Pompe disease. A positive result would mean the treatment plan helped keep function stable, improved outcomes, or gave useful information for future care decisions.
Because both studies are Phase 3, they are meant to provide stronger evidence in larger groups than early-stage trials. The patient groups are different, but both trials are aimed at understanding how Alglucosidase Alfa is used in real-world Pompe disease care.